Biologics

Biologics

Biologics are the drugs that are obtained from living organism or their components such as nucleic acid, protein, sugars, and cells. These are used in the treatment of a wide variety of diseases such as cancer, autoimmune disease and inflammatory conditions. Unlike conventional small-molecule drugs that are chemically synthesized. Biologics are synthesized using a living system such as yeast, or mammalian cells and may also be synthesized from natural sources or genetic engineering.

Biologics are available in different dosage forms such as vaccines, monoclonal antibodies, and gene therapy. because of its complex molecule nature, it requires specialized manufacturing and storage conditions.

the global biologics market is projected to expand significantly with a CAGR of ~9.0. This is attributed to the rising incidence of chronic diseases including cancer, diabetes, and arthritis coupled with the rising prevalence of the autoimmune disease worldwide. For instance, according to the international diabetes federation 2021 report, there were approximately 537 million adults living with diabetes globally, This is predicted to rise to 643 million by 2030 and 783 million by 2045. diabetes worldwide. Biologics are used in the treatment of such diseases due to its effectiveness. Thus, the above-mentioned factors are anticipated to fuel the global market growth.

• Based on product type, the market is segmented into monoclonal antibodies, interleukins, growth factors and gene therapy. The monoclonal antibodies are expected to witness significant growth during the forecast period. owing to their application in treating and managing chronic diseases such as cancer, psoriasis, Crohn’s diseases, diabetes, cancer and many more. These act by attacking the target cell, inducing conformational changes in receptors without causing harm to the healthy cells.
• Based on application, the market is segmented into diabetes, cancer, autoimmune, and tumour. The segment is expected to witness significant market growth during the forecast period. the ongoing research & development project in the field of cancer such as gene therapies and anti-sera therapies is anticipated to fuel the market growth. Furthermore, the increasing adoption of biologics for cancer treatment owing to its ability of the biologics to enhance the support of the immune system in the detection of tumor cells, and fight cancer by turning off its signals. Thus, preventing the suppression of the immune system.
• For a better understanding of the market adoption of the healthcare contract research organisation, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (UK, Germany, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Rest of World. North America dominated the biologics market in 2021 due to the rise in healthcare expenditure coupled with the presence of a major player in this region. Additionally, the research & development of biologics in the treatment of non-communicable chronic diseases further propels the market growth in this region during the forecasting period.
• Some of the major players operating in the market include Amgen Inc., Eli Lilly and Company, and GSK plc. , AbbVie Inc., F. Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., Novartis Pharmaceuticals Corporation, Johnson & Johnson Services, Inc., Merck & Co., Inc.